| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR9 |
| Uniprot No | P51686 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-369aa |
| 氨基酸序列 | MTPTDFTSPIPNMADDYGSESTSSMEDYVNFNFTDFYCEKNNVRQFASHFLPPLYWLVFIVGALGNSLVILVYWYCTRVKTMTDMFLLNLAIADLLFLVTLPFWAIAAADQWKFQTFMCKVVNSMYKMNFYSCVLLIMCISVDRYIAIAQAMRAHTWREKRLLYSKMVCFTIWVLAAALCIPEILYSQIKEESGIAICTMVYPSDESTKLKSAVLTLKVILGFFLPFVVMACCYTIIIHTLIQAKKSSKHKALKVTITVLTVFVLSQFPYNCILLVQTIDAYAMFISNCAVSTNIDICFQVTQTIAFFHSCLNPVLYVFVGERFRRDLVKTLKNLGCISQAQWVSFTRREGSLKLSSMLLETTSGALSL |
| 预测分子量 | 43.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCR9重组蛋白的3篇参考文献，涵盖结构、功能及药物开发方向：
---
1. **文献名称**：*Structural basis of ligand interaction with the chemokine receptor CCR9*
**作者**：Steen, A. 等
**摘要**：本研究通过冷冻电镜解析了CCR9与其天然配体CCL25的复合物结构，揭示了受体激活的关键结构域，为设计靶向CCR9的炎症性疾病药物提供了分子基础。
2. **文献名称**：*Expression and functional characterization of recombinant CCR9 in mammalian cell systems*
**作者**：Zhang, Y. 等
**摘要**：报道了在HEK293细胞中高效表达功能性CCR9重组蛋白的方法，并通过钙流实验验证其与CCL25结合后的信号传导活性，为体外药物筛选提供可靠模型。
3. **文献名称**：*CCR9 antagonism in inflammatory bowel disease: Insights from preclinical models*
**作者**：Campbell, J.J. 等
**摘要**：利用重组CCR9蛋白筛选小分子拮抗剂，并在结肠炎小鼠模型中验证其抑制T细胞肠道浸润的效果，证明靶向CCR9在治疗克罗恩病中的潜力。
---
注：以上文献信息为示例性质，实际研究中建议通过PubMed或Web of Science核对具体文献。如需补充实验方向(如信号机制)，可进一步扩展。
CCR9 (C-C chemokine receptor type 9) is a G protein-coupled receptor (GPCR) primarily expressed on immune cells, particularly T lymphocytes, dendritic cells, and gut-associated leukocytes. It plays a critical role in mediating cell migration and immune responses, especially in the gastrointestinal tract. The receptor binds specifically to its natural ligand, CCL25 (chemokine ligand 25), a chemokine predominantly secreted by epithelial cells in the small intestine and thymus. This CCR9-CCL25 axis is essential for directing immune cell trafficking to mucosal tissues, contributing to intestinal homeostasis, immune surveillance, and inflammatory processes.
Recombinant CCR9 protein is a lab-engineered version of the receptor, typically produced using expression systems like mammalian cells, insect cells, or bacteria. It retains the functional domains of native CCR9. including its seven transmembrane helices and extracellular regions involved in ligand binding. Researchers utilize recombinant CCR9 to study receptor-ligand interactions, signaling pathways (e.g., MAPK/ERK and PI3K/Akt), and its role in diseases such as inflammatory bowel disease (IBD), colorectal cancer, and autoimmune disorders. It also serves as a tool for drug discovery, enabling high-throughput screening of antagonists or agonists targeting CCR9-mediated pathways.
The development of recombinant CCR9 has advanced therapeutic research, particularly in designing drugs to modulate gut-specific immune responses. Inhibitors of CCR9 are being explored for treating Crohn's disease and ulcerative colitis, while its overexpression in certain cancers highlights its potential as a diagnostic or prognostic biomarker. Structural studies using recombinant protein have further elucidated conformational changes during activation, informing the design of targeted therapies with reduced off-target effects.
×
